安进药物Tavneos关键研究被撤稿
2026-06-29 19:06:45
据彭博社报道，安进公司(Amgen Inc.)用于批准其口服药Tavneos的一项临床试验，周一被《新英格兰医学杂志》撤稿，或令该药持续销售面临风险。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
股票市场 | 财通福鑫定开混合6月30日停牌
